within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX09_DiroximelFumarate;

model DiroximelFumarate
  extends Pharmacolibrary.Drugs.ATC.L.L04AX09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AX09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Diroximel fumarate is an oral immunomodulatory drug used for the treatment of relapsing forms of multiple sclerosis (MS). It is a prodrug that is rapidly converted to monomethyl fumarate (MMF), the active metabolite which exerts anti-inflammatory and neuroprotective effects. It is an FDA- and EMA-approved medication as of 2019 and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers (fasted/fed), reporting on monomethyl fumarate (active metabolite) following 231 mg diroximel fumarate twice daily oral administration.</p><h4>References</h4><ol><li><p>Kuchimanchi, M, et al., &amp; Penner, N (2022). Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis. <i>Neurology and therapy</i> 11(1) 353â€“371. DOI:<a href=\"https://doi.org/10.1007/s40120-021-00316-6\">10.1007/s40120-021-00316-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35041178/\">https://pubmed.ncbi.nlm.nih.gov/35041178</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DiroximelFumarate;
